HUYABIO Validates Protective Mechanism for Antiarrhythmic Drug HBI-3000 in AF Patients, Paving the Way for a New Era in Atrial Fibrillation Treatment
Excerpt from the Press Release:
HBI-3000 Aims to Fill Critical Gaps in Atrial Fibrillation Care; Key Data to be Presented at the American Heart Association Annual Meeting
SAN DIEGO, Nov. 14, 2024 /PRNewswire/ — HUYABIO International today announced the presentation of new patient data for HBI-3000, an antiarrhythmic drug (AAD) with a unique protective profile for the treatment of atrial fibrillation (AF), one of the most common and serious heart conditions worldwide.
This promising drug will be highlighted in a moderated poster presentation in the session entitled “The Return of Antiarrhythmic Drug Therapy: A New Age with New Therapeutics” at the American Heart Association (AHA) Annual Meeting in Chicago, IL, from November 16-18, 2024.
Dr. Mireille Gillings, President, CEO & Executive Chair at HUYABIO, said, “Intravenous (IV) HBI-3000 and our second-generation oral form, HBI-3020, represent the first true control of AF in more than a decade. The opportunity for acute to chronic care protection has been missing from treatments. HUYABIO’s goal is to provide clinicians with a safe, effective solution that puts total control of AF at the forefront.”
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?